Cancer patients develop cachexia due to systemic inflammation, negative protein and energy balance. Esperer Onco Nutrition (EON) has come up with
innovative nutritional supplements (EON Therapy) that help patients take the rigours of cancer therapy thereby improving
prognosis and Quality of Life(QoL).
This Post-marketing surveillance study was undertaken on 38 volunteers
to assess the impact of EON therapy on cachexia and QoL of patients undergoing
curative treatment. Body weight and biochemical parameters of the volunteers
were recorded at each visit. Volunteers were assessed using ECOG Scale and
Malnutrition Screening Tool (MST) to assess impact of nutritional supplements
on QoL. Weight loss was observed in most of the patients for first two visits
but the patients gained weight over subsequent visits and average weight at end
of the study was higher than initial weight. At the end of study 22 of 38
volunteers gained weight and 7 volunteers maintained initial weight. The
biochemical parameters either showed improvement or remained same. The QoL
analysis indicated a marked improvement in physical wellness and nutritional
status and no adverse effects were reported. In conclusion, the study
underlines importance of research based on nutritional supplements
for cancer patients for better disease management and prognosis.
References
[1]
Porporato, P.E. (2016) Understanding Cachexia as a Cancer Metabolism Syndrome. Oncogenesis, 5, Article No. e200. https://doi.org/10.1038/oncsis.2016.3
[2]
Marceca, G.P., Londhe, P. and Calore, F. (2020) Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options. Frontiers in Oncology, 10, Article No. 298.
https://doi.org/10.3389/fonc.2020.00298
[3]
Hébuterne, X., Lemarié, E., Michallet, M., de Montreuil, C.B., Schneider, S.M. and Goldwasser, F. (2014) Prevalence of Malnutrition and Current Use of Nutrition Support in Patients with Cancer. Journal of Parenteral and Enteral Nutrition, 38, 196-204. https://doi.org/10.1177/0148607113502674
[4]
Bruggeman, A.R., Kamal, A.H., LeBlanc, T.W., Ma, J.D., Baracos, V.E. and Roeland, E.J. (2016) Cancer Cachexia: Beyond Weight Loss. Journal of Oncology Practice, 12, 1163-1171. https://doi.org/10.1200/JOP.2016.016832
[5]
Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P.C., Deutz, N.E.P., Erickson, N., et al. (2017) ESPEN Expert Group Recommendations for Action against Cancer-Related Malnutrition. Clinical Nutrition, 36, 1187-1196.
https://doi.org/10.1016/j.clnu.2017.06.017
[6]
Lu, Z., Yang, L., Yu, J., Lu, M., Zhang, X., Li, J., Zhou, J., Wang, X., Gong, J., Gao, J., Li, J., Li, Y. and Shen, L. (2014) Change of Body Weight and Macrophage Inhibitory Cytokine-1 during Chemotherapy in Advanced Gastric Cancer: What Is Their Clinical Significance? PLoS ONE, 9, Article ID: e88553.
https://doi.org/10.1371/journal.pone.0088553
[7]
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., Krznaric, Z., Laird, B., Larsson, M., Laviano, A., Mühlebach, S., Muscaritoli, M., Oldervoll, L., Ravasco, P., Solheim, T., Strasser, F., de van der Schueren, M. and Preiser, J.C. (2017) ESPEN Guidelines on nutrition in cancer patients. Clinical Nutrition, 36, 11-48.
https://doi.org/10.1016/j.clnu.2016.07.015
[8]
Fearon, K., Arends, J. and Baracos, V. (2013) Understanding the Mechanisms and Treatment Options in Cancer Cachexia. Nature Review Clinical Oncology, 10, 90-99.
https://doi.org/10.1038/nrclinonc.2012.209
[9]
Aapro, M., Arends, J., Bozzetti, F., Fearon, K., Grunberg, S.M., Herrstedt, J., Hopkinson, J., Jacquelin-Ravel, N., Jatoi, A., Kaasa, S. and Strasser F. (2014) Early Recognition of Malnutrition and Cachexia in the Cancer Patient: A Position Paper of a European School of Oncology Task Force. Annals of Oncology, 25, 1492-1499.
https://doi.org/10.1093/annonc/mdu085
[10]
Bozzetti, F., Arends, J., Lundholm, K., Micklewright, A., Zurcher, G. and Muscaritoli, M. (2009) ESPEN Guidelines on Parenteral Nutrition: Non-Surgical Oncology. Clinical Nutrition, 28, 445-454. https://doi.org/10.1016/j.clnu.2009.04.011
[11]
Cotogni, P., Pedrazzoli, P., De Waele, E., Aprile, G., Farina, G., Stragliotto, S., De Lorenzo, F. and Caccialanza, R. (2019) Nutritional Therapy in Cancer Patients Receiving Chemoradiotherapy: Should We Need Stronger Recommendations to Act for Improving Outcomes? Journal of Cancer, 10, 4318-4325.
https://doi.org/10.7150/jca.31611
[12]
Cotogni, P. (2016) Enteral versus Parenteral Nutrition in Cancer Patients: Evidences and Controversies. Annals of Palliative Medicine, 5, 42-49.
[13]
August, D.A. and Huhmann, M.B. (2009) ASPEN Clinical Guidelines: Nutrition Support Therapy during Adult Anticancer Treatment and in Hematopoietic Cell Transplantation. Journal of Parenteral and Enteral Nutrition, 33, 472-500.
https://doi.org/10.1177/0148607109341804
[14]
Yalcin, S., Gumus, M., Oksuzoglu, B., Ozdemir, F., Evrensel, T., Sarioglu, A.A., Sahin, B., Mandel, N.M. and Goker, E. (2019) Nutritional Aspect of Cancer Care in Medical Oncology Patients. Clinical Therapy, 41, 2382-2396.
https://doi.org/10.1016/j.clinthera.2019.09.006
[15]
Azam, F., Latif, M.F., Farooq, A., Tirmazy, S.H., AlShahrani, S., Bashir, S. and Bukhari, N. (2019) Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. Case Reports in Oncology, 12, 728-736. https://doi.org/10.1159/000503095
[16]
Di Bella, A., Croisier, E., Blake, C., Pelecanos, A., Bauer, J. and Brown, T. (2020) Assessing the Concurrent Validity and Interrater Reliability of Patient-Led Screening Using the Malnutrition Screening Tool in the Ambulatory Cancer Care Outpatient Setting. Journal of the Academy of Nutrition and Dietetics, 120, 1210-1215.
https://doi.org/10.1016/j.jand.2019.10.015
[17]
Kubrak, C., Olson, K., Jha, N., Jensen, L., McCargar, L., Seikaly, H., Harris, J., Scrimger, R., Parliament, M. and Baracos, V.E. (2010) Nutrition Impact Symptoms: Key Determinants of Reduced Dietary Intake, Weight Loss, and Reduced Functional Capacity of Patients with Head and Neck Cancer before Treatment. Head Neck, 32, 290-300. https://doi.org/10.1002/hed.21174
[18]
Batista, G.A., Souza, A.L., Marin, D.M., Sider, M., Melhado, V.C., Fernandes, A.M. and Alegre, S.M. (2017) Body Composition, Resting Energy Expenditure and Inflammatory Markers: Impact in Users of Depot Medroxyprogesterone Acetate after 12 Months Follow-Up. Archives of Endocrinology and Metabolism, 61, 70-75.
https://doi.org/10.1590/2359-3997000000202
[19]
Akbulut, G. (2011) New Perspective for Nutritional Support of Cancer Patients: Enteral/Parenteral Nutrition. Experimental and Therapeutic Medicine, 2, 675-684.
https://doi.org/10.3892/etm.2011.247
[20]
Tan, B.H., Birdsell, L.A., Martin, L., Baracos, V.E. and Fearon K.C. (2009) Sarcopenia in An Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer. Clinical Cancer Research, 15, 6973-6979.
https://doi.org/10.1158/1078-0432.CCR-09-1525
[21]
Prado, C.M., Lieffers, J.R., McCargar, L.J., Reiman, T., Sawyer, M.B., Martin, L. and Baracos V.E. (2008) Prevalence and Clinical Implications of Sarcopenic Obesity in Patients with Solid Tumours of the Respiratory and Gastrointestinal Tracts: A Population-Based Study. The Lancet Oncology, 9, 629-635.
https://doi.org/10.1016/S1470-2045(08)70153-0
[22]
Prado, C.M., Antoun, S., Sawyer, M.B. and Baracos, V.E. (2011) Two Faces of Drug Therapy in Cancer: Drug-Related Lean Tissue Loss and Its Adverse Consequences to Survival and Toxicity. Current Opinion in Nutrition and Metabolic Care, 14, 250-254. https://doi.org/10.1097/MCO.0b013e3283455d45
[23]
Mir, O., Coriat, R., Blanchet, B., Durand, J.P., Boudou-Rouquette, P., Michels, J., Ropert, S., Vidal, M., Pol, S., Chaussade, S. and Goldwasser, F. (2012) Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma. PLoS ONE, 7, Article ID: e37563.
https://doi.org/10.1371/journal.pone.0037563
[24]
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y. and Li, Y. (2021) Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention. Signal Transduction and Targeted Therapy, 6, Article No. 263.
https://doi.org/10.1038/s41392-021-00658-5
[25]
Greten, F.R. and Grivennikov, S.I. (2019) Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 51, 27-41.
https://doi.org/10.1016/j.immuni.2019.06.025
[26]
Hanahan, D. and Weinberg R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. https://doi.org/10.1016/j.cell.2011.02.013
[27]
Straub, R.H. (2012) Evolutionary Medicine and Chronic Inflammatory State—Known and New Concepts in Pathophysiology. Journal of Molecular Medicine, 90, 523-534.
https://doi.org/10.1007/s00109-012-0861-8
[28]
Winter, A., MacAdams, J. and Chevalier, S. (2012) Normal Protein Anabolic Response to Hyperaminoacidemia in Insulin-Resistant Patients with Lung Cancer Cachexia. Clinical Nutrition, 31, 765-773. https://doi.org/10.1016/j.clnu.2012.05.003
[29]
Straub, R.H., Cutolo, M., Buttgereit, F. and Pongratz G. (2010) Energy Regulation and Neuroendocrine-Immune Control in Chronic Inflammatory Diseases. Journal of Internal Medicine, 267, 543-560.
https://doi.org/10.1111/j.1365-2796.2010.02218.x
[30]
Honors, M.A. and Kinzig, K.P. (2012) The Role of Insulin Resistance in the Development of Muscle Wasting during Cancer Cachexia. Journal of Cachexia, Sarcopenia and Muscle, 3, 5-11. https://doi.org/10.1007/s13539-011-0051-5
[31]
Aoyagi, T., Terracina, K.P., Raza, A., Matsubara, H. and Takabe, K. (2015) Cancer Cachexia, Mechanism and Treatment. World J Gastrointestinal Oncology, 7, 17-29.
https://doi.org/10.4251/wjgo.v7.i4.17
[32]
Tan, B.H., Fladvad, T., Braun, T.P., Vigano, A., Strasser, F., Deans, D.A., Skipworth, R.J., Solheim, T.S., Damaraju, S., Ross, J.A., Kaasa, S., Marks, D.L., Baracos, V.E., Skorpen, F. and Fearon, K.C. (2012) P-Selectin Genotype Is Associated with the Development of Cancer Cachexia. EMBO Molecular Medicine, 4, 462-471.
https://doi.org/10.1002/emmm.201200231
[33]
Das, S.K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., Gorkiewicz, G., Tamilarasan, K.P., Kumari, P., Trauner, M., Zimmermann, R., Vesely, P., Haemmerle, G., Zechner, R. and Hoefler G. (2011) Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia. Science, 333, 233-238.
https://doi.org/10.1126/science.1198973
[34]
Arends, J. (2018) Struggling with Nutrition in Patients with Advanced Cancer: Nutrition and Nourishment—Focusing on Metabolism and Supportive care. Annals of Oncology, 29, ii27-ii34. https://doi.org/10.1093/annonc/mdy093
[35]
Giordano, A. and Tommonaro, G. (2019) Curcumin and Cancer. Nutrients, 11, Article No. 2376. https://doi.org/10.3390/nu11102376
[36]
Kawata, A., Murakami, Y., Suzuki, S. and Fujisawa, S. (2018) Anti-Inflammatory Activity of β-Carotene, Lycopene and Tri-n-Butylborane, a Scavenger of Reactive Oxygen Species. In Vivo, 32, 255-264. https://doi.org/10.21873/invivo.11232
[37]
Lee, J.H., Park, E., Jin, H.J., Lee, Y., Choi, S.J., Lee, G.W., Chang, P.S. and Paik, H.D. (2017) Anti-Inflammatory and Anti-Genotoxic Activity of Branched Chain Amino Acids (BCAA) in Lipopolysaccharide (LPS) Stimulated RAW 264.7 Macrophages. Food Science and Biotechnology, 26, 1371-1377.
https://doi.org/10.1007/s10068-017-0165-4
[38]
Costello, L.C. and Franklin, R.B. (2012) Cytotoxic/Tumor Suppressor Role of Zinc for the Treatment of Cancer: An Enigma and an Opportunity. Expert Review of Anticancer Therapy, 12, 121-128. https://doi.org/10.1586/era.11.190
[39]
Cheng, J. and Ouwehand, A.C. (2020) Gastroesophageal Reflux Disease and Probiotics: A Systematic Review. Nutrients, 12, Article No. 132.
https://doi.org/10.3390/nu12010132
